25 August 2017 - - The complement C3 inhibitor of US-based autoimmune disease therapeutics developer Apellis Pharmaceuticals, Inc., APL-2, met its primary endpoint in a Phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA), an advanced form of age-related macular degeneration, the company said.
At 12 months, APL-2, administered monthly via intravitreal injection, showed a 29% (p=0.008) reduction in the rate of GA lesion growth compared to sham. With every other month administration, a 20% (p=0.067) reduction was observed.
Additionally, in a post hoc analysis, a greater effect was observed during the second six months of the study: a reduction in growth rate of 47% (p